$5650 | Single User
$6650 | Multi User
$8150 | Corporate License
$10000 | Global License

Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020
[Published by MarketsandMarkets]

Published by MarketsandMarkets: 30 Jul 2015 | 41791 | In Stock

Introduction

The global biosimulation market is expected to reach USD 2,107.99 million by 2020 from USD 1,034.93 million in 2015, at a CAGR of 15.29% between 2015 and 2020. By product, the market includes software and services. Based on application, the market is segmented into drug discovery, drug development, and others (defense, industrial bioprocessing, nutraceuticals, and agri-food production). The drug development application segment is further classified into preclinical testing and clinical trials. Preclinical testing includes ADME/Tox and PK/PD applications. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The drug development segment will hold the largest share of the biosimulation market in 2015. The other applications segment is expected to grow at the highest rate.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share in the global biosimulation market in 2015. Europe is expected to register the fastest growth.

Market growth is majorly driven by the availability of R&D investments in biotechnology and pharmaceutical industries. Other growth factors include the need to curtail drug discovery & development costs, technological advancements, growth in the biologics and biosimilars markets, and the increased use of personalized medicines.

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the global biosimulation market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates. The report provides qualitative insights about growth rates, and market drivers for all subsegments. It maps market sizes and growth rates for each subsegment and identifies segments poised for rapid growth in each geographic segment. The report also includes company profiles of market leaders.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:

• Product Development: Product portfolios of the top players in the biosimulation market.

• Competitive Assessment: In-depth assessment of the business segments and product portfolios of the leading players in the biosimulation market.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biosimulation products and services across geographies.

Table of Contents
for Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020 [Published by MarketsandMarkets]

  • TABLE OF CONTENTS

    1 INTRODUCTION 15

    1.1 OBJECTIVES OF THE STUDY 15

    1.2 MARKET DEFINITION 15

    1.2.1 MARKETS COVERED 16

    1.2.2 YEARS CONSIDERED FOR THE STUDY 16

    1.3 CURRENCY 17

    1.4 STAKEHOLDERS 17

    2 RESEARCH METHODOLOGY 18

    2.1 MARKET SIZE ESTIMATION 19

    2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 22

    2.3 MARKET SHARE ESTIMATION 23

    2.3.1 KEY DATA FROM SECONDARY SOURCES 23

    2.3.2 KEY DATA FROM PRIMARY SOURCES 23

    2.3.3 ASSUMPTIONS FOR THE STUDY 24

    3 EXECUTIVE SUMMARY 25

    4 PREMIUM INSIGHTS 29

    4.1 LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOSIMULATION MARKET 29

    4.2 LIFE CYCLE ANALYSIS, BY REGION (2015–2020) 30

    5 MARKET OVERVIEW 32

    5.1 INTRODUCTION 33

    5.2 MARKET SEGMENTATION 33

    5.2.1 BY PRODUCT 33

    5.2.2 BY APPLICATION 34

    5.2.3 BY END USER 34

    5.3 MARKET DYNAMICS 35

    5.3.1 DRIVERS 36

    5.3.1.1 Growth in the pharmaceutical and biotechnology industries 36

    5.3.1.2 Increase in R&D investments in the pharmaceutical and biotechnology industries 36

    5.3.1.3 Technological advancements 37

    5.3.1.4 Need to curtail drug discovery and development costs 37

    5.3.1.5 Growth in the biologics and biosimilars market and increased use of personalized medicines 37

    5.3.2 RESTRAINTS 39

    5.3.2.1 Lack of standardization 39

    5.3.2.2 Lack of trained professionals 39

    5.3.3 OPPORTUNITIES 40

    5.3.3.1 Emerging applications 40

    5.3.4 CHALLENGES 41

    5.3.4.1 Limited knowledge of biological systems and processes 41

    5.3.5 TRENDS 42

    5.3.5.1 Collaborations of universities and research labs with suppliers 42

    6 BIOSIMULATION MARKET, BY PRODUCT 43

    6.1 INTRODUCTION 44

    6.2 SOFTWARE 46

    6.2.1 PK/PD MODELING AND SIMULATION SOFTWARE 48

    6.2.2 MOLECULAR MODELING AND SIMULATION SOFTWARE 49

    6.2.3 PBPK MODELING AND SIMULATION SOFTWARE 50

    6.2.4 TOXICITY PREDICTION SOFTWARE 50

    6.2.5 TRIAL DESIGN SOFTWARE 51

    6.2.6 OTHER SOFTWARE 52

    6.3 SERVICES 53

    6.3.1 IN-HOUSE SERVICES 55

    6.3.2 EXTERNAL/CONTRACT SERVICES 55

    7 BIOSIMULATION MARKET, BY APPLICATION 57

    7.1 INTRODUCTION 58

    7.2 DRUG DEVELOPMENT 59

    7.2.1 PRECLINICAL TESTING 62

    7.2.1.1 PK/PD 64

    7.2.1.2 ADME/Tox 65

    7.2.2 CLINICAL TRIALS 66

    7.3 DRUG DISCOVERY 66

    7.3.1 TARGET IDENTIFICATION AND VALIDATION 69

    7.3.2 LEAD IDENTIFICATION AND OPTIMIZATION 70

    7.4 OTHER APPLICATIONS 71

    8 BIOSIMULATION MARKET, BY END USER 73

    8.1 INTRODUCTION 74

    8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 76

    8.3 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 78

    8.4 CONTRACT RESEARCH ORGANIZATIONS 80

    8.5 REGULATORY AUTHORITIES 81

    8.6 OTHER END USERS 83

    9 GLOBAL BIOSIMULATION MARKET, BY REGION 85

    9.1 INTRODUCTION 86

    9.2 NORTH AMERICA 88

    9.3 EUROPE 95

    9.4 ASIA 101

    9.5 REST OF THE WORLD (ROW) 107

    10 COMPETITIVE LANDSCAPE 113

    10.1 INTRODUCTION 113

    10.2 STRATEGIC OVERVIEW 113

    10.3 LEADING PLAYERS IN THE BIOSIMULATION MARKET 114

    10.4 COMPETITIVE SITUATION AND TRENDS 115

    10.4.1 PRODUCT UPGRADATION 115

    10.4.2 AGREEMENTS, COLLABORATIONS, EXPANSIONS, AND PARTNERSHIPS 116

    10.4.3 NEW PRODUCT AND SERVICE LAUNCHES 117

    10.4.4 ACQUISITIONS 118

    10.4.5 OTHER DEVELOPMENTS 118

    11 COMPANY PROFILES 120

    11.1 INTRODUCTION 120

    11.2 CERTARA USA, INC. 121

    11.3 SIMULATION PLUS INC. 123

    11.4 DASSAULT SYSTÈMES SA 125

    11.5 SCHRÖDINGER INC. 127

    11.6 ADVANCED CHEMISTRY DEVELOPMENT, INC. 129

    11.7 CHEMICAL COMPUTING GROUP, INC. 131

    11.8 ENTELOS HOLDING CORPORATION 132

    11.9 GENEDATA AG 133

    11.10 PHYSIOMICS PLC 134

    11.11 RHENOVIA PHARMA LTD. 136

    *Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

    12 APPENDIX 137

    12.1 INSIGHTS OF INDUSTRY EXPERTS 137

    12.2 DISCUSSION GUIDE 138

    12.3 OTHER DEVELOPMENTS 141

    12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 146

    12.5 AVAILABLE CUSTOMIZATIONS 147

    12.6 RELATED REPORTS 148

List Of Tables
in Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020 [Published by MarketsandMarkets]

LIST OF TABLES


TABLE 1 BIOSIMULATION MARKET SUMMARY 25

TABLE 2 GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES ALONG WITH INCREASE IN R&D INVESTMENTS IN THESE INDUSTRIES IS PROPELLING THE GROWTH OF THE BIOSIMULATION MARKET 38

TABLE 3 LACK OF STANDARDIZATION TO RESTRICT MARKET GROWTH 40

TABLE 4 EMERGING APPLICATIONS PRESENT SIGNIFICANT GROWTH OPPORTUNITIES FOR THE BIOSIMULATION MARKET 41

TABLE 5 LIMITED KNOWLEDGE OF BIOLOGICAL SYSTEMS AND PROCESSES POSE A CHALLENGE FOR THE BIOSIMULATION MARKET 41

TABLE 6 COLLABORATIONS OF UNIVERSITIES AND RESEARCH LABS WITH SUPPLIERS IS A MAJOR TREND OBSERVED IN THIS MARKET 42

TABLE 7 BIOSIMULATION MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 45

TABLE 8 BIOSIMULATION SOFTWARE MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION) 47

TABLE 9 BIOSIMULATION SOFTWARE MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 48

TABLE 10 BIOSIMULATION MARKET SIZE FOR PK/PD MODELING AND SIMULATION SOFTWARE, BY REGION, 2013–2020 (USD MILLION) 48

TABLE 11 BIOSIMULATION MARKET SIZE FOR MOLECULAR MODELING AND SIMULATION SOFTWARE, BY REGION, 2013–2020 (USD MILLION 49

TABLE 12 BIOSIMULATION MARKET SIZE FOR PBPK MODELING AND SIMULATION SOFTWARE, BY REGION, 2013–2020 (USD MILLION) 50

TABLE 13 BIOSIMULATION MARKET SIZE FOR TOXICITY PREDICTION SOFTWARE, BY REGION, 2013–2020 (USD MILLION) 51

TABLE 14 BIOSIMULATION MARKET SIZE FOR TRIAL DESIGN SOFTWARE, BY REGION,

2013–2020 (USD MILLION) 51

TABLE 15 BIOSIMULATION MARKET SIZE FOR OTHER SOFTWARE, BY REGION,

2013–2020 (USD MILLION) 52

TABLE 16 BIOSIMULATION SERVICES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION) 53

TABLE 17 BIOSIMULATION SERVICES MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 54

TABLE 18 BIOSIMULATION MARKET SIZE FOR IN-HOUSE SERVICES, BY REGION,

2013–2020 (USD MILLION) 55

TABLE 19 BIOSIMULATION MARKET SIZE FOR EXTERNAL/CONTRACT SERVICES

, BY REGION, 2013–2020 (USD MILLION) 56

TABLE 20 BIOSIMULATION MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION) 59

TABLE 21 BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT, BY APPLICATION, 2013–2020 (USD MILLION ) 60

TABLE 22 BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT, BY REGION,

2013–2020 (USD MILLION) 61

TABLE 23 BIOSIMULATION MARKET SIZE FOR PRECLINICAL TESTING, BY APPLICATION, 2013–2020 (USD MILLION ) 62

TABLE 24 BIOSIMULATION MARKET SIZE FOR PRECLINICAL TESTING, BY REGION,

2013–2020 (USD MILLION ) 63

TABLE 25 BIOSIMULATION MARKET SIZE FOR PK/PD, BY REGION,

2013–2020 (USD MILLION) 64

TABLE 26 BIOSIMULATION MARKET SIZE FOR ADME/TOX, BY REGION,

2013–2020 (USD MILLION) 65

TABLE 27 BIOSIMULATION MARKET SIZE FOR CLINICAL TRIALS, BY REGION,

2013–2020 (USD MILLION) 66

TABLE 28 BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY, BY APPLICATION,

2013–2020 (USD MILLION ) 67

TABLE 29 BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY, BY REGION,

2013–2020 (USD MILLION ) 68

TABLE 30 BIOSIMULATION MARKET SIZE FOR TARGET IDENTIFICATION AND OPTIMIZATION, BY REGION, 2013–2020 (USD MILLION) 69

TABLE 31 BIOSIMULATION MARKET SIZE FOR LEAD IDENTIFICATION AND OPTIMIZATION,

BY REGION, 2013–2020 (USD MILLION) 70

TABLE 32 BIOSIMULATION MARKET SIZE FOR OTHER APPLICATIONS, BY REGION,

2013–2020 (USD MILLION ) 72

TABLE 33 BIOSIMULATION MARKET SIZE, BY END USER, 2013–2020 (USD MILLION) 75

TABLE 34 BIOSIMULATION MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2013–2020 (USD MILLION) 77

TABLE 35 BIOSIMULATION MARKET SIZE FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2013–2020 (USD MILLION) 79

TABLE 36 BIOSIMULATION MARKET SIZE FOR CROS, BY REGION, 2013–2020 (USD MILLION) 81

TABLE 37 BIOSIMULATION MARKET SIZE FOR REGULATORY AUTHORITIES, BY REGION, 2013–2020 (USD MILLION) 82

TABLE 38 BIOSIMULATION MARKET SIZE FOR OTHER END USERS, BY REGION,

2013–2020 (USD MILLION) 84

TABLE 39 BIOSIMULATION MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 87

TABLE 40 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY PRODUCT,

2013–2020 (USD MILLION) 90

TABLE 41 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY SOFTWARE,

2013–2020 (USD MILLION) 91

TABLE 42 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY SERVICE,

2013–2020 (USD MILLION) 91

TABLE 43 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY APPLICATION,

2013–2020 (USD MILLION) 92

TABLE 44 NORTH AMERICA: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2013–2020 (USD MILLION) 93

TABLE 45 NORTH AMERICA: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS, BY TYPE, 2013–2020 (USD MILLION) 93

TABLE 46 NORTH AMERICA: BIOSIMULATION MARKET SIZE, BY END USER,

2013–2020 (USD MILLION) 94

TABLE 47 EUROPE: BIOSIMULATION MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 97

TABLE 48 EUROPE: BIOSIMULATION MARKET SIZE, BY SOFTWARE,

2013–2020 (USD MILLION) 98

TABLE 49 EUROPE: BIOSIMULATION MARKET SIZE, BY SERVICE, 2013–2020 (USD MILLION) 98

TABLE 50 EUROPE: BIOSIMULATION MARKET SIZE, BY APPLICATION,

2013–2020 (USD MILLION) 99

TABLE 51 EUROPE: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS, BY TYPE, 2013–2020 (USD MILLION) 99

TABLE 52 EUROPE: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2013–2020 (USD MILLION) 100

TABLE 53 EUROPE: BIOSIMULATION MARKET SIZE, BY END USER,

2013–2020 (USD MILLION) 101

TABLE 54 ASIA: BIOSIMULATION MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 102

TABLE 55 ASIA: BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2013–2020 (USD MILLION) 103

TABLE 56 ASIA: BIOSIMULATION MARKET SIZE, BY SERVICE, 2013–2020 (USD MILLION) 103

TABLE 57 ASIA: BIOSIMULATION MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION) 104

TABLE 58 ASIA: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS,

BY TYPE, 2013–2020 (USD MILLION) 105

TABLE 59 ASIA: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2013–2020 (USD MILLION) 105

TABLE 60 ASIA: BIOSIMULATION MARKET SIZE, BY END USER, 2013–2020 (USD MILLION) 106

TABLE 61 ROW: BIOSIMULATION MARKET SIZE, BY PRODUCT, 2013–2020 (USD MILLION) 108

TABLE 62 ROW: BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2013–2020 (USD MILLION) 109

TABLE 63 ROW: BIOSIMULATION MARKET SIZE, BY SERVICE, 2013–2020 (USD MILLION) 109

TABLE 64 ROW: BIOSIMULATION MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION) 110

TABLE 65 ROW: BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT APPLICATIONS,

BY TYPE, 2013–2020 (USD MILLION) 111

TABLE 66 ROW: BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY APPLICATIONS,

BY TYPE, 2013–2020 (USD MILLION) 111

TABLE 67 ROW: BIOSIMULATION MARKET SIZE, BY END USER, 2013–2020 (USD MILLION) 112

TABLE 68 RANK OF COMPANIES IN THE GLOBAL BIOSIMULATION MARKET, 2015 114

TABLE 69 MARKET DEVELOPMENTS BETWEEN 2013–2015 115

TABLE 70 PRODUCT UPGRADATION, 2013–2015 116

TABLE 71 AGREEMENTS, COLLABORATIONS, EXPANSIONS, AND PARTNERSHIPS,

2013–2015 116

TABLE 72 NEW PRODUCT AND SERVICE LAUNCHES, 2013–2015 117

TABLE 73 ACQUISITIONS, 2013–2015 118

TABLE 74 OTHER DEVELOPMENTS, 2013–2015 119

List Of Figures, Charts and Diagrams
in Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020 [Published by MarketsandMarkets]

LIST OF FIGURES


FIGURE 1 GLOBAL BIOSIMULATION MARKET 16

FIGURE 2 RESEARCH DESIGN 18

FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 20

FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 20

FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 21

FIGURE 6 DATA TRIANGULATION METHODOLOGY 22

FIGURE 7 BIOSIMULATION MARKET SIZE, BY PRODUCT, 2015 VS. 2020 (USD MILLION) 26

FIGURE 8 BIOSIMULATION MARKET SIZE, BY APPLICATION, 2015 VS. 2020 (USD MILLION) 26

FIGURE 9 BIOSIMULATION MARKET SIZE, BY END USER, 2015 VS. 2020 (USD MILLION) 27

FIGURE 10 BIOSIMULATION MARKET SIZE, BY REGION, 2015 VS. 2020 (USD MILLION) 28

FIGURE 11 GLOBAL BIOSIMULATION MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD 29

FIGURE 12 SOFTWARE PRODUCT SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2015 29

FIGURE 13 EUROPE TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020 30

FIGURE 14 EUROPEAN MARKET SHOWCASES LUCRATIVE GROWTH OPPORTUNITIES 30

FIGURE 15 BIOSIMULATION MARKET SEGMENTATION: BY PRODUCT 33

FIGURE 16 BIOSIMULATION MARKET SEGMENTATION: BY APPLICATION 34

FIGURE 17 BIOSIMULATION MARKET SEGMENTATION: BY END USER 34

FIGURE 18 GROWTH IN THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES ALONG WITH INCREASE IN R&D INVESTMENTS IN THESE INDUSTRIES WILL DRIVE THE BIOSIMULATION MARKET 35

FIGURE 19 NEW PHARMACEUTICAL DRUG LAUNCHES (2003–2013) 36

FIGURE 20 BIOSIMULATION MARKET SEGMENTATION, BY PRODUCT 44

FIGURE 21 BIOSIMULATION MARKET, BY PRODUCT, 2015 (USD MILLION) 45

FIGURE 22 BIOSIMULATION SOFTWARE MARKET SIZE, BY TYPE, 2015 VS. 2020 (USD MILLION) 46

FIGURE 23 BIOSIMULATION SOFTWARE MARKET SIZE, BY REGION, 2015 VS. 2020 (USD MILLION) 47

FIGURE 24 BIOSIMULATION SERVICES MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION) 53

FIGURE 25 BIOSIMULATION SERVICES MARKET SIZE, BY REGION, 2013–2020 (USD MILLION) 54

FIGURE 26 BIOSIMULATION MARKET SEGMENTATION, BY APPLICATION 58

FIGURE 27 DRUG DEVELOPMENT SEGMENT TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN 2015 58

FIGURE 28 BIOSIMULATION MARKET SIZE FOR DRUG DEVELOPMENT, BY APPLICATION,

2015 VS. 2020 (USD MILLION ) 60

FIGURE 29 NORTH AMERICA EXPECTED TO BE THE LARGEST REGIONAL SEGMENT FOR DRUG DEVELOPMENT APPLICATIONS 61

FIGURE 30 BIOSIMULATION MARKET SIZE FOR PRECLINICAL TESTING, BY APPLICATION,

2015 VS. 2020 (USD MILLION) 62

FIGURE 31 NORTH AMERICA EXPECTED TO BE THE LARGEST REGIONAL SEGMENT FOR PRECLINICAL TESTING APPLICATIONS 63

FIGURE 32 BIOSIMULATION MARKET SIZE FOR DRUG DISCOVERY, BY APPLICATION, 2015 VS. 2020 (USD MILLION ) 67

FIGURE 33 EUROPE IS THE FASTEST-GROWING REGIONAL SEGMENT FOR DRUG DISCOVERY APPLICATIONS 68

FIGURE 34 OTHER APPLICATIONS MARKET IN EUROPE TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD 71

FIGURE 35 BIOSIMULATION MARKET, BY END USER 74

FIGURE 36 BIOSIMULATION MARKET SIZE, BY END USER, 2015 (USD MILLION) 74

FIGURE 37 NUMBER OF BIOTECHNOLOGY AND PHARMACEUTICAL PATENTS GRANTED IN 2012, BY REGION 76

FIGURE 38 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SEGMENT TO WITNESS HIGHEST GROWTH IN EUROPE 77

FIGURE 39 PUBLIC-SECTOR RESEARCH FUNDING DRIVING THE GROWTH OF THE ACADEMIC & GOVERNMENT RESEARCH INSTITUTES END-USER SEGMENT 78

FIGURE 40 NORTH AMERICA DOMINATES MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 79

FIGURE 41 NORTH AMERICA EXPECTED TO DOMINATE BIOSIMULATION MARKET FOR CROS 80

FIGURE 42 EUROPE IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE BIOSIMULATION MARKET FOR REGULATORY AUTHORITIES 82

FIGURE 43 EUROPE TO WITNESS HIGHEST GROWTH IN THE BIOSIMULATION MARKET FOR OTHER END USERS IN THE FORECAST PERIOD 83

FIGURE 44 BIOSIMULATION MARKET SEGMENTATION, BY REGION 86

FIGURE 45 NORTH AMERICA TO DOMINATE THE GLOBAL BIOSIMULATION MARKET IN THE FORECAST PERIOD 86

FIGURE 46 BIOSIMULATION MARKET IN EUROPE TO WITNESS THE HIGHEST GROWTH FROM 2015 TO 2020 87

FIGURE 47 NORTH AMERICA: MARKET SNAPSHOT 89

FIGURE 48 BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN NORTH AMERICA IN 2015 90

FIGURE 49 DRUG DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION APPLICATIONS MARKET IN NORTH AMERICA BY 2020 92

FIGURE 50 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO FORM THE LARGEST END-USER SEGMENT IN NORTH AMERICA IN 2015 94

FIGURE 51 EUROPE: MARKET SNAPSHOT 96

FIGURE 52 BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE EUROPEAN BIOSIMULATION MARKET IN 2015 97

FIGURE 53 DRUG DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION APPLICATIONS MARKET IN EUROPE BY 2020 99

FIGURE 54 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION END-USER MARKET IN EUROPE IN 2015 100

FIGURE 55 BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN ASIA IN 2015 102

FIGURE 56 DRUG DEVELOPMENT APPLICATION SEGMENT TO DOMINATE THE BIOSIMULATION MARKET IN ASIA BY 2020 104

FIGURE 57 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR THE LARGEST SHARE OF THE BIOSIMULATION END-USER MARKET IN ASIA IN 2015 106

FIGURE 58 BIOSIMULATION SOFTWARE TO COMMAND THE LARGEST SHARE OF THE ROW BIOSIMULATION MARKET IN 2015 108

FIGURE 59 DRUG DEVELOPMENT APPLICATION SEGMENT TO COMMAND THE LARGEST SHARE OF THE BIOSIMULATION MARKET IN THE ROW REGION BY 2020 110

FIGURE 60 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES END-USER SEGMENT TO DOMINATE THE ROW MARKET FOR BIOSIMULATION IN 2015 112

FIGURE 61 KEY DEVELOPMENTS IN THE BIOSIMULATION MARKET, 2013-2015 113

FIGURE 62 GEOGRAPHICAL MIX OF THE TOP 4 MARKET PLAYERS 120

FIGURE 63 COMPANY SNAPSHOT: SIMULATION PLUS INC. 123

FIGURE 64 COMPANY SNAPSHOT: DASSAULT SYSTÈMES SA 125

FIGURE 65 COMPANY SNAPSHOT: PHYSIOMICS PLC 134

Additional Details

Publisher

MarketsandMarkets

Publisher Information

Reference

41791 | HIT 3629

Number of Pages

149

Report Format

PDF

MarketsandMarkets Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022
“Global biosimulation market projected to grow at a CAGR of 15.9%”The biosimulation market is expect...
03 Jan 2018 by MarketsandMarkets USD $5,650 More Info
Global Biosimulation Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 – 2022
Biosimulation is explained as a computer-aided mathematical simulation of biological processes and s...
09 Apr 2016 by Occams Business Research USD $3,900 More Info
Global Biosimulation Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 – 2022
Biosimulation is explained as a computer-aided mathematical simulation of biological processes and s...
09 Apr 2016 by Occams Business Research USD $5,900 More Info

This report is published by MarketsandMarkets

Download Free Report Summary PDF

Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020 [Published by MarketsandMarkets] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)